dose stratum | personyears | cases | HR (95% CI) | p.value |
---|---|---|---|---|
atc_group: A01 (stomatological preparations) | ||||
no use | 41,961,553 | 15,611 | 1.0 (ref) | |
>2 prescr. | 3,532 | 0 | 4.6e-05 (1.1e-90-2e+81) | 9.20e-01 |
25th percentile | 164,415 | 103 | 1.2 (0.97-1.4) | 9.30e-02 |
50th percentile | 93,435 | 66 | 1.2 (0.97-1.6) | 9.30e-02 |
75th percentile | 49,585 | 42 | 1.4 (1-1.9) | 3.80e-02 |
90th percentile | 20,295 | 18 | 1.5 (0.93-2.3) | 1.00e-01 |
atc_group: A02 (drugs for acid related disorders) | ||||
no use | 35,906,365 | 12,136 | 1.0 (ref) | |
>2 prescr. | 1,280,651 | 542 | 0.98 (0.89-1.1) | 5.70e-01 |
25th percentile | 2,185,808 | 1,265 | 1.2 (1.1-1.3) | 1.50e-09 |
50th percentile | 1,839,907 | 1,204 | 1.1 (1.1-1.2) | 1.60e-04 |
75th percentile | 819,954 | 529 | 0.96 (0.88-1.1) | 4.20e-01 |
90th percentile | 260,129 | 164 | 0.92 (0.79-1.1) | 2.90e-01 |
atc_group: A03 (drugs for functional gastrointestinal disorders) | ||||
no use | 41,289,868 | 15,256 | 1.0 (ref) | |
>2 prescr. | 7,597 | 0 | 1.8e-05 (3.4e-102-9.4e+91) | 9.20e-01 |
25th percentile | 463,399 | 228 | 1.1 (0.95-1.2) | 2.20e-01 |
50th percentile | 283,205 | 175 | 1.3 (1.1-1.5) | 4.40e-04 |
75th percentile | 172,072 | 117 | 1.4 (1.1-1.6) | 7.70e-04 |
90th percentile | 76,673 | 64 | 1.7 (1.3-2.2) | 3.20e-05 |
atc_group: A06 (drugs for constipation) | ||||
no use | 41,746,574 | 15,218 | 1.0 (ref) | |
>2 prescr. | 7,456 | 0 | 1.7e-05 (1.1e-94-2.6e+84) | 9.20e-01 |
25th percentile | 268,070 | 323 | 1.7 (1.5-1.9) | 8.50e-20 |
50th percentile | 141,029 | 187 | 1.8 (1.6-2.1) | 3.70e-16 |
75th percentile | 80,286 | 81 | 1.5 (1.2-1.8) | 6.10e-04 |
90th percentile | 49,399 | 31 | 1 (0.71-1.4) | 9.20e-01 |
atc_group: A11 (vitamins) | ||||
no use | 40,125,099 | 14,318 | 1.0 (ref) | |
>2 prescr. | 583,103 | 333 | 1.3 (1.1-1.4) | 5.40e-05 |
25th percentile | 512,545 | 370 | 1.4 (1.2-1.5) | 1.00e-09 |
50th percentile | 632,256 | 528 | 1.3 (1.2-1.5) | 4.00e-11 |
75th percentile | 313,084 | 239 | 1 (0.92-1.2) | 4.90e-01 |
90th percentile | 126,728 | 52 | 0.56 (0.43-0.74) | 3.80e-05 |
atc_group: A12 (mineral supplements) | ||||
no use | 40,208,012 | 14,247 | 1.0 (ref) | |
>2 prescr. | 540,251 | 389 | 1.2 (1.1-1.3) | 4.10e-04 |
25th percentile | 626,885 | 539 | 1.3 (1.2-1.4) | 1.70e-10 |
50th percentile | 545,576 | 427 | 1.1 (1-1.3) | 7.30e-03 |
75th percentile | 258,517 | 164 | 0.88 (0.76-1) | 1.10e-01 |
90th percentile | 113,573 | 74 | 0.93 (0.73-1.2) | 5.10e-01 |
atc_group: B01 (antithrombotic agents) | ||||
no use | 34,650,302 | 8,827 | 1.0 (ref) | |
>2 prescr. | 2,129,634 | 1,860 | 1.3 (1.3-1.4) | 5.00e-30 |
25th percentile | 2,646,001 | 2,474 | 1.2 (1.2-1.3) | 2.70e-15 |
50th percentile | 2,062,564 | 2,009 | 1.1 (1.1-1.2) | 3.80e-05 |
75th percentile | 599,070 | 526 | 0.92 (0.84-1) | 5.30e-02 |
90th percentile | 205,244 | 144 | 0.83 (0.7-0.98) | 2.50e-02 |
atc_group: B03 (antianemic preparations) | ||||
no use | 39,710,443 | 14,126 | 1.0 (ref) | |
>2 prescr. | 658,883 | 452 | 1.3 (1.2-1.4) | 6.60e-08 |
25th percentile | 857,919 | 616 | 1.3 (1.2-1.4) | 8.20e-08 |
50th percentile | 566,786 | 369 | 1.1 (0.97-1.2) | 1.90e-01 |
75th percentile | 332,957 | 190 | 0.91 (0.78-1) | 1.80e-01 |
90th percentile | 165,828 | 87 | 0.76 (0.62-0.94) | 1.20e-02 |
atc_group: C01 (cardiac therapy) | ||||
no use | 40,086,414 | 13,679 | 1.0 (ref) | |
>2 prescr. | 464,666 | 420 | 1.2 (1.1-1.3) | 8.70e-04 |
25th percentile | 756,000 | 720 | 1.2 (1.1-1.3) | 8.00e-05 |
50th percentile | 588,008 | 642 | 1.2 (1.1-1.3) | 3.20e-06 |
75th percentile | 285,167 | 300 | 1.1 (1-1.3) | 2.70e-02 |
90th percentile | 112,560 | 79 | 0.84 (0.68-1.1) | 1.30e-01 |
atc_group: C07 (beta blocking agents) | ||||
no use | 36,167,406 | 10,486 | 1.0 (ref) | |
>2 prescr. | 1,698,829 | 1,572 | 1.5 (1.4-1.6) | 1.80e-54 |
25th percentile | 2,132,260 | 1,876 | 1.2 (1.2-1.3) | 3.50e-15 |
50th percentile | 1,675,625 | 1,418 | 1 (0.99-1.1) | 1.30e-01 |
75th percentile | 470,849 | 405 | 0.97 (0.88-1.1) | 5.30e-01 |
90th percentile | 147,845 | 83 | 0.75 (0.6-0.93) | 8.10e-03 |
atc_group: C09 (agents acting on the renin-angiotensin system) | ||||
no use | 34,127,144 | 10,184 | 1.0 (ref) | |
>2 prescr. | 2,748,962 | 1,853 | 1.1 (1-1.1) | 4.90e-02 |
25th percentile | 2,746,811 | 1,818 | 0.9 (0.86-0.95) | 6.70e-05 |
50th percentile | 1,917,893 | 1,431 | 0.87 (0.83-0.92) | 2.70e-06 |
75th percentile | 592,305 | 485 | 0.85 (0.78-0.93) | 5.70e-04 |
90th percentile | 159,701 | 69 | 0.49 (0.38-0.62) | 2.40e-09 |
atc_group: D01 (antifungals for dermatological use) | ||||
no use | 39,693,243 | 14,327 | 1.0 (ref) | |
>2 prescr. | 10,924 | 0 | 1.6e-05 (2.2e-97-1.2e+87) | 9.20e-01 |
25th percentile | 1,267,365 | 696 | 1.2 (1.1-1.3) | 4.20e-06 |
50th percentile | 571,228 | 348 | 1.2 (1.1-1.4) | 1.60e-04 |
75th percentile | 535,040 | 342 | 1.2 (1.1-1.3) | 1.90e-03 |
90th percentile | 215,015 | 127 | 0.96 (0.81-1.1) | 6.60e-01 |
atc_group: G03 (sex hormones and modulators of the genital system) | ||||
no use | 34,253,116 | 13,673 | 1.0 (ref) | |
>2 prescr. | 1,845,965 | 481 | 1.2 (1.1-1.3) | 1.70e-03 |
25th percentile | 2,908,602 | 743 | 1.2 (1.1-1.3) | 2.40e-04 |
50th percentile | 2,087,963 | 547 | 1 (0.95-1.1) | 3.60e-01 |
75th percentile | 896,099 | 286 | 1 (0.9-1.1) | 8.20e-01 |
90th percentile | 301,070 | 110 | 0.95 (0.78-1.1) | 5.70e-01 |
atc_group: G04 (urologicals) | ||||
no use | 38,702,552 | 11,885 | 1.0 (ref) | |
>2 prescr. | 997,317 | 885 | 1.4 (1.3-1.5) | 1.30e-17 |
25th percentile | 979,236 | 1,131 | 1.6 (1.5-1.7) | 7.70e-51 |
50th percentile | 979,057 | 1,188 | 1.5 (1.4-1.6) | 5.00e-41 |
75th percentile | 449,466 | 551 | 1.4 (1.3-1.5) | 1.90e-13 |
90th percentile | 185,187 | 200 | 1.2 (1.1-1.4) | 3.00e-03 |
atc_group: H01 (pituitary and hypothalamic hormones and analogues) | ||||
no use | 41,932,195 | 15,742 | 1.0 (ref) | |
>2 prescr. | 1,845 | 0 | 0.00012 (6e-123-2.3e+114) | 9.50e-01 |
25th percentile | 152,325 | 32 | 2.1 (1.5-3) | 3.00e-05 |
50th percentile | 137,791 | 30 | 1.9 (1.3-2.7) | 6.60e-04 |
75th percentile | 52,630 | 22 | 1.6 (1-2.4) | 3.70e-02 |
90th percentile | 16,029 | 14 | 1.5 (0.88-2.5) | 1.40e-01 |
atc_group: H02 (corticosteroids for systemic use) | ||||
no use | 38,533,637 | 14,039 | 1.0 (ref) | |
>2 prescr. | 12,626 | 0 | 6e-06 (5e-120-7.1e+108) | 9.30e-01 |
25th percentile | 1,816,421 | 801 | 0.92 (0.85-0.98) | 1.50e-02 |
50th percentile | 1,104,438 | 557 | 0.92 (0.84-1) | 5.30e-02 |
75th percentile | 615,561 | 329 | 0.82 (0.73-0.91) | 2.80e-04 |
90th percentile | 210,131 | 114 | 0.72 (0.6-0.87) | 4.90e-04 |
atc_group: J01 (antibacterials for systemic use) | ||||
no use | 20,538,423 | 7,149 | 1.0 (ref) | |
>2 prescr. | 5,732,343 | 2,157 | 0.98 (0.94-1) | 4.80e-01 |
25th percentile | 6,698,580 | 2,696 | 0.99 (0.95-1) | 6.60e-01 |
50th percentile | 5,507,217 | 2,161 | 0.89 (0.85-0.94) | 6.50e-06 |
75th percentile | 2,657,311 | 1,097 | 0.85 (0.8-0.91) | 1.40e-06 |
90th percentile | 1,158,940 | 580 | 0.89 (0.81-0.96) | 5.50e-03 |
atc_group: L01 (antineoplastic agents) | ||||
no use | 42,169,103 | 15,782 | 1.0 (ref) | |
>2 prescr. | 1,740 | 0 | 4.5e-05 (1.5e-122-1.4e+113) | 9.40e-01 |
25th percentile | 53,352 | 24 | 0.56 (0.38-0.84) | 5.00e-03 |
50th percentile | 33,298 | 19 | 0.75 (0.48-1.2) | 2.20e-01 |
75th percentile | 20,841 | 9 | 0.6 (0.31-1.2) | 1.30e-01 |
90th percentile | 14,481 | 6 | 0.55 (0.24-1.2) | 1.40e-01 |
atc_group: M01 (antiinflammatory and antirheumatic products) | ||||
no use | 22,646,864 | 7,937 | 1.0 (ref) | |
>2 prescr. | 4,844,955 | 1,652 | 1 (0.94-1) | 8.60e-01 |
25th percentile | 7,060,628 | 2,753 | 1.1 (1-1.1) | 1.60e-03 |
50th percentile | 4,130,258 | 1,762 | 1.1 (1-1.1) | 6.40e-03 |
75th percentile | 2,583,838 | 1,230 | 1 (0.98-1.1) | 1.40e-01 |
90th percentile | 1,026,271 | 506 | 0.93 (0.85-1) | 1.30e-01 |
atc_group: M05 (drugs for treatment of bone diseases) | ||||
no use | 41,147,195 | 14,797 | 1.0 (ref) | |
>2 prescr. | 279,070 | 314 | 1.6 (1.5-1.8) | 3.10e-17 |
25th percentile | 326,083 | 315 | 1.4 (1.2-1.5) | 6.80e-08 |
50th percentile | 311,203 | 241 | 1 (0.92-1.2) | 5.40e-01 |
75th percentile | 167,692 | 139 | 1.1 (0.92-1.3) | 3.50e-01 |
90th percentile | 61,572 | 34 | 0.76 (0.54-1.1) | 1.10e-01 |
atc_group: N02 (analgesics) | ||||
no use | 28,053,325 | 9,094 | 1.0 (ref) | |
>2 prescr. | 3,810,108 | 1,554 | 1.1 (1-1.1) | 5.80e-02 |
25th percentile | 4,355,738 | 2,114 | 1.2 (1.1-1.2) | 3.10e-10 |
50th percentile | 3,549,109 | 1,867 | 1.2 (1.1-1.3) | 1.10e-11 |
75th percentile | 2,001,974 | 1,010 | 1.1 (1-1.2) | 9.80e-04 |
90th percentile | 522,560 | 201 | 0.89 (0.77-1) | 9.70e-02 |
atc_group: N03 (antiepileptics) | ||||
no use | 40,365,777 | 14,656 | 1.0 (ref) | |
>2 prescr. | 327,467 | 211 | 1.5 (1.3-1.7) | 8.80e-09 |
25th percentile | 605,775 | 405 | 1.6 (1.5-1.8) | 7.20e-23 |
50th percentile | 621,626 | 376 | 1.5 (1.3-1.7) | 1.70e-14 |
75th percentile | 284,974 | 156 | 1.3 (1.1-1.5) | 2.70e-03 |
90th percentile | 87,196 | 36 | 0.96 (0.69-1.3) | 8.30e-01 |
atc_group: N05 (psycholeptics) | ||||
no use | 31,695,517 | 9,374 | 1.0 (ref) | |
>2 prescr. | 2,722,322 | 1,435 | 1.4 (1.3-1.5) | 1.40e-33 |
25th percentile | 3,265,296 | 2,108 | 1.5 (1.4-1.5) | 1.20e-53 |
50th percentile | 2,852,777 | 1,911 | 1.3 (1.3-1.4) | 5.00e-31 |
75th percentile | 1,303,642 | 793 | 1.3 (1.2-1.4) | 4.50e-11 |
90th percentile | 453,260 | 219 | 1.1 (0.97-1.3) | 1.10e-01 |
atc_group: N06 (psychoanaleptics) | ||||
no use | 36,045,124 | 11,733 | 1.0 (ref) | |
>2 prescr. | 1,399,581 | 814 | 1.9 (1.8-2) | 5.50e-69 |
25th percentile | 2,115,503 | 1,510 | 2.3 (2.2-2.4) | 6.40e-195 |
50th percentile | 1,781,068 | 1,202 | 1.9 (1.8-2) | 5.50e-93 |
75th percentile | 725,177 | 457 | 1.5 (1.4-1.7) | 2.40e-19 |
90th percentile | 226,360 | 124 | 1.3 (1.1-1.5) | 5.60e-03 |
atc_group: N07 (other nervous system drugs) | ||||
no use | 41,273,429 | 15,620 | 1.0 (ref) | |
>2 prescr. | 6,269 | 0 | 4.7e-05 (2.8e-108-7.7e+98) | 9.30e-01 |
25th percentile | 382,903 | 85 | 0.73 (0.59-0.91) | 4.20e-03 |
50th percentile | 407,404 | 85 | 0.67 (0.54-0.82) | 1.80e-04 |
75th percentile | 159,351 | 38 | 0.71 (0.52-0.98) | 3.70e-02 |
90th percentile | 63,458 | 12 | 0.95 (0.54-1.7) | 8.70e-01 |
atc_group: R03 (drugs for obstructive airway diseases) | ||||
no use | 36,976,015 | 13,589 | 1.0 (ref) | |
>2 prescr. | 1,478,237 | 514 | 0.89 (0.82-0.98) | 1.30e-02 |
25th percentile | 1,569,100 | 675 | 0.96 (0.89-1) | 3.40e-01 |
50th percentile | 1,455,375 | 672 | 0.82 (0.76-0.89) | 9.60e-07 |
75th percentile | 604,046 | 301 | 0.76 (0.68-0.86) | 3.50e-06 |
90th percentile | 210,042 | 89 | 0.61 (0.49-0.75) | 3.50e-06 |
atc_group: R05 (cough and cold preparations) | ||||
no use | 34,148,841 | 12,149 | 1.0 (ref) | |
>2 prescr. | 27,387 | 0 | 6.1e-06 (1.4e-97-2.6e+86) | 9.10e-01 |
25th percentile | 3,236,960 | 1,373 | 0.98 (0.93-1) | 5.70e-01 |
50th percentile | 3,237,747 | 1,458 | 0.93 (0.88-0.98) | 1.20e-02 |
75th percentile | 1,172,868 | 600 | 0.91 (0.84-0.99) | 3.40e-02 |
90th percentile | 469,012 | 260 | 0.86 (0.76-0.97) | 1.40e-02 |
atc_group: S01 (ophthalmologicals) | ||||
no use | 32,977,748 | 10,608 | 1.0 (ref) | |
>2 prescr. | 18,364 | 0 | 6.6e-06 (1e-102-4.2e+91) | 9.20e-01 |
25th percentile | 4,576,507 | 2,276 | 1.1 (1.1-1.2) | 4.50e-07 |
50th percentile | 2,956,602 | 1,786 | 1.2 (1.2-1.3) | 1.40e-16 |
75th percentile | 1,423,283 | 941 | 1.1 (1-1.2) | 3.50e-03 |
90th percentile | 340,312 | 229 | 0.89 (0.78-1) | 7.20e-02 |
atc_group: S03 (ophthalmological and otological preparations) | ||||
no use | 40,965,577 | 15,291 | 1.0 (ref) | |
>2 prescr. | 4,785 | 0 | 4.5e-05 (2e-90-1e+81) | 9.20e-01 |
25th percentile | 620,714 | 249 | 0.86 (0.76-0.97) | 1.60e-02 |
50th percentile | 409,045 | 170 | 0.83 (0.72-0.97) | 1.80e-02 |
75th percentile | 186,014 | 88 | 0.86 (0.69-1.1) | 1.50e-01 |
90th percentile | 106,679 | 42 | 0.65 (0.48-0.88) | 5.90e-03 |